175 related articles for article (PubMed ID: 32543072)
1. The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays.
Exner T; Rigano J; Favaloro EJ
Int J Lab Hematol; 2020 Jun; 42 Suppl 1():41-48. PubMed ID: 32543072
[TBL] [Abstract][Full Text] [Related]
2. Simple method for removing DOACs from plasma samples.
Exner T; Michalopoulos N; Pearce J; Xavier R; Ahuja M
Thromb Res; 2018 Mar; 163():117-122. PubMed ID: 29407622
[TBL] [Abstract][Full Text] [Related]
3. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants.
Ząbczyk M; Kopytek M; Natorska J; Undas A
Clin Chem Lab Med; 2019 Aug; 57(9):1374-1381. PubMed ID: 30763261
[TBL] [Abstract][Full Text] [Related]
4. Potential usefulness of activated charcoal (DOAC remove®) for dRVVT testing in patients receiving Direct Oral AntiCoagulants.
Jourdi G; Delrue M; Stepanian A; Valaize J; Foulon-Pinto G; Demagny J; Duchemin J; Nedelec-Gac F; Darnige L; Curis E; Delavenne X; Gaussem P; Siguret V; Gouin-Thibault I
Thromb Res; 2019 Dec; 184():86-91. PubMed ID: 31710863
[TBL] [Abstract][Full Text] [Related]
5. Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging anticoagulants.
Exner T; Ahuja M; Ellwood L
Clin Chem Lab Med; 2019 Apr; 57(5):690-696. PubMed ID: 30427777
[TBL] [Abstract][Full Text] [Related]
6. DOAC-Remove abolishes the effect of direct oral anticoagulants on activated protein C resistance testing in real-life venous thromboembolism patients.
Kopytek M; Ząbczyk M; Malinowski KP; Undas A; Natorska J
Clin Chem Lab Med; 2020 Feb; 58(3):430-437. PubMed ID: 31539350
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the DOAC-Stop Procedure by LC-MS/MS Assays for Determining the Residual Activity of Dabigatran, Rivaroxaban, and Apixaban.
Slavik L; Jacova J; Friedecky D; Ulehlova J; Tauber Z; Prochazkova J; Hlusi A; Palova M
Clin Appl Thromb Hemost; 2019; 25():1076029619872556. PubMed ID: 31523979
[TBL] [Abstract][Full Text] [Related]
8. Resolving DOAC interference on aPTT, PT, and lupus anticoagulant testing by the use of activated carbon.
Frans G; Meeus P; Bailleul E
J Thromb Haemost; 2019 Aug; 17(8):1354-1362. PubMed ID: 31102433
[TBL] [Abstract][Full Text] [Related]
9. Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban.
Platton S; Hunt C
Int J Lab Hematol; 2019 Apr; 41(2):227-233. PubMed ID: 30468572
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of DOAC Filter, a new device to remove direct oral anticoagulants from plasma samples.
Sevenet PO; Cucini V; Hervé T; Depasse F; Carlo A; Contant G; Mathieu O
Int J Lab Hematol; 2020 Oct; 42(5):636-642. PubMed ID: 32567799
[TBL] [Abstract][Full Text] [Related]
11. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting.
Antovic A; Norberg EM; Berndtsson M; Rasmuson A; Malmström RE; Skeppholm M; Antovic J
Thromb Haemost; 2017 Aug; 117(9):1700-1704. PubMed ID: 28640321
[TBL] [Abstract][Full Text] [Related]
12. Laboratory testing for lupus anticoagulant (LA) in patients taking direct oral anticoagulants (DOACs): potential for false positives and false negatives.
Favaloro EJ; Mohammed S; Curnow J; Pasalic L
Pathology; 2019 Apr; 51(3):292-300. PubMed ID: 30665674
[TBL] [Abstract][Full Text] [Related]
13. Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants.
Reda S; Brügelmann A; Müller J; Oldenburg J; Pötzsch B; Rühl H
Sci Rep; 2020 Jul; 10(1):12221. PubMed ID: 32699227
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests.
Favresse J; Lardinois B; Sabor L; Devalet B; Vandepapeliere J; Braibant M; Lessire S; Chatelain B; Jacqmin H; Douxfils J; Mullier F
TH Open; 2018 Apr; 2(2):e202-e209. PubMed ID: 31249943
[TBL] [Abstract][Full Text] [Related]
15. Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants.
Flieder T; Weiser M; Eller T; Dittrich M; von Bargen K; Alban S; Kuhn J; Knabbe C; Birschmann I
Thromb Res; 2018 May; 165():101-106. PubMed ID: 29627719
[TBL] [Abstract][Full Text] [Related]
16. Direct oral anticoagulant adsorption: Impact on lupus anticoagulant testing-Review of the literature and evaluation on spiked and patient samples.
De Kesel PM; Devreese KMJ
J Thromb Haemost; 2020 Aug; 18(8):2003-2017. PubMed ID: 32400112
[TBL] [Abstract][Full Text] [Related]
17. Unveiling the complex effects of direct oral anticoagulants on dilute Russell's viper venom time assays.
Hillarp A; Strandberg K; Gustafsson KM; Lindahl TL
J Thromb Haemost; 2020 Aug; 18(8):1866-1873. PubMed ID: 32294291
[TBL] [Abstract][Full Text] [Related]
18. Resolving DOAC interference on antithrombin activity testing on a FXa based method by the use of activated carbon.
Vercruyssen J; Meeus P; Bailleul E
Clin Chim Acta; 2023 Jan; 538():216-220. PubMed ID: 36574540
[TBL] [Abstract][Full Text] [Related]
19. Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: A real-life study.
Gay J; Duchemin J; Imarazene M; Fontenay M; Jourdi G
Int J Lab Hematol; 2019 Dec; 41(6):738-744. PubMed ID: 31487115
[TBL] [Abstract][Full Text] [Related]
20. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
